Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Moderna’s Shift to Cancer Company Lifts Stock Up 177%

The New York Times – Business:

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Rebecca Robbins

in

Bancel, Stephane, Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Health and Human Services Department, Kennedy, Robert F Jr, Merck & Company Inc, Moderna Inc, Trump, Donald J, Vaccination and Immunization
←Can We Do Anything About Tick-Borne Diseases Like Alpha-Gal Syndrome?
How Usher Gets Ready for a Show→

More posts

  • Glastonbury 2027 tickets sell out in 42 minutes

  • Niccolò Pasqualetti Spring 2027 Ready-to-Wear

  • Lily Brant Followed in Her Mom’s Alaïa Footsteps—After Practicing in Heels on a Treadmill

  • Modric ‘ashamed’ of Croatia’s ‘catastrophic night’

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube